CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.13BCNY1.07B · vs all stocks (USD)
Revenue (TTM)
1.44BCNY215.39M · vs all stocks (USD)
Profit Margin
-29.94%Beta
0.0830xvs all stocks
52-Week Change
-16.42%vs all stocks
Market Capitalization
7.13BCNY1.07B · vs all stocks (USD)
Enterprise Value
6.56BCNY980.27M · vs all stocks (USD)
Price to Sales (TTM)
4.81xPrice to Book (MRQ)
1.33xEnterprise to Revenue
4.55xEnterprise to EBITDA
-57.83xGross Margin
49.03%Profit Margin
-29.94%Operating Margin
0.36%Return on Assets (TTM)
-1.56%Return on Equity (TTM)
-8.25%Revenue (TTM)
1.44BCNY215.39M · vs all stocks (USD)
Revenue per Share (TTM)
0.4690CNYUpdated Sep 21, 2026Quarterly Revenue Growth
-27.40%Gross Profit (TTM)
665.78MCNY99.42M · vs all stocks (USD)
EBITDA (TTM)
105.02MCNY15.68M · vs all stocks (USD)
Net Income (TTM)
-431.80MCNY-64.48M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-27.38%Operating Cash Flow (TTM)
91.18MCNY13.62M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
225.76MCNY33.71M · vs all stocks (USD)
5-Year Average Dividend Yield
1.26%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
1.37BCNYFY2025 · Dec 31, 2025Revenue
1.75BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
977.54MCNYFY2025 · Dec 31, 2025Gross Profit
771.05MCNYFY2025 · Dec 31, 2025Operating Income
-177.66MCNY-26.53M · vs all stocks (USD)
Pre-tax Income
-527.07MCNYFY2025 · Dec 31, 2025Income Tax Expense
-31.80MCNYFY2025 · Dec 31, 2025Net Income
-495.26MCNYFY2025 · Dec 31, 2025EBIT
-462.74MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
105.02MCNYFY2025 · Dec 31, 2025Research & Development
125.26MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
442.45MCNYFY2025 · Dec 31, 2025Other Operating Expenses
43.02MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
103.34MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
64.32MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1144CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1144CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
3.12BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
3.12BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-495.26MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
138.17MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-291.37MCNYFY2025 · Dec 31, 2025Free Cash Flow
-381.68MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.35BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-495.26MCNYFY2025 · Dec 31, 2025Other Non-cash Items
72.88MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
63.15MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
67.86MCNYFY2025 · Dec 31, 2025Capital Expenditures
-90.31MCNYFY2025 · Dec 31, 2025Net Acquisitions
782.46KCNYFY2025 · Dec 31, 2025Purchase of Investments
-270.88MCNYFY2025 · Dec 31, 2025Sale of Investments
289.93MCNYFY2025 · Dec 31, 2025Other Investing Activity
4.03MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-66.44MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.89BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-2.10BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-55.29MCNYFY2025 · Dec 31, 2025Other Financing Charges
-298.70MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-564.43MCNYFY2025 · Dec 31, 2025Shares Outstanding
3.18BSharesUpdated Sep 21, 2026Float Shares
2.21BSharesUpdated Sep 21, 2026% Held by Insiders
34.30%vs all stocks
% Held by Institutions
1.43%vs all stocks
Total Cash (MRQ)
3.58BCNY534.80M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.13CNYUpdated Sep 21, 2026Total Debt (MRQ)
1.85BCNY275.66M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2804xCurrent Ratio (MRQ)
2.18xBook Value per Share (MRQ)
1.64CNYUpdated Sep 21, 2026Total Assets
10.07BCNY1.50B · vs all stocks (USD)
Total Current Assets
5.25BCNYFY2025 · Dec 31, 2025Total Liabilities
1.06BCNYFY2025 · Dec 31, 2025Total Non-current Assets
4.82BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.06BCNYFY2025 · Dec 31, 2025Cash
3.40BCNYFY2025 · Dec 31, 2025Cash Equivalents
1.77MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.41BCNYFY2025 · Dec 31, 2025Other Short-term Investments
77.02MCNYFY2025 · Dec 31, 2025Accounts Receivable
411.00MCNYFY2025 · Dec 31, 2025Inventory
639.91MCNYFY2025 · Dec 31, 2025Accounts Payable
412.47MCNYFY2025 · Dec 31, 2025Short-term Debt
1.29BCNYFY2025 · Dec 31, 2025Other Current Liabilities
13.74MCNYFY2025 · Dec 31, 2025Long-term Debt
476.25MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
326.32MCNYFY2025 · Dec 31, 2025Common Stock (Book)
3.18BCNYFY2025 · Dec 31, 2025Retained Earnings
1.56BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
6.74BCNY1.01B · vs all stocks (USD)
52-Week Low
1.71CNYUpdated Sep 21, 202652-Week High
3.10CNYUpdated Sep 21, 202652-Week Change
-16.42%vs all stocks
Beta
0.0830xvs all stocks
50-Day MA
2.24CNYUpdated Sep 21, 2026200-Day MA
2.40CNYUpdated Sep 21, 2026Avg 10-Day Volume
47.25MSharesUpdated Sep 21, 2026Avg 30-Day Volume
63.73MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-0.1400CNYUpdated Sep 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.49Profit Margin: -0.30
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Enovis Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Guilin Sanjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MannKind Corporation
Tier 1ProductionApproval-Gated PipelineRule
Inkon Life Tech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CK Life Sciences Int'l.,
Tier 1ProductionApproval-Gated PipelineFlowInterface
Lifetech Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule
Xiangyu Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zylox-Tonbridge Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Hongyu Wuzhou Medica Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Kanion Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule